Will Pfizer return to the top 1 pharmaceutical company with its $26 billion sales blessing?

Medicine King will change hands in 2021?

Xiumile, whose sales in 2020 has approached 20 billion U.

From the previously announced 2020 global best-selling drug rankings, it can be seen that there are three drugs with sales exceeding 10 billion U.

01 BNT162b2 becomes the airborne champion?

Will there be a dark horse in the 2021 best-selling drug list?

The answer is yes, it may even be an airborne champion.

Judging from Pfizer’s first quarter 2021 financial report recently announced, the first quarter sales of Pfizer’s new crown vaccine BNT162b2 reached 3.

Pfizer disclosed in its financial report that as of May 3, Pfizer and its partner BioNTech have shipped about 430 million doses of BNT162b2 to 91 countries and regions around the world, and have reached agreements with Israel and Canada for vaccine purchases after 2021.

According to CNN, Reuters and other foreign media reports on the 11th, the FDA has approved the use of Pfizer's new crown vaccine for the 12 to 15-year-old young people, and the vaccination will begin as early as this Thursday.

Image source: Pfizer 2021Q1 earnings report

In addition to expanding the applicable population of vaccines, Pfizer CEO Aberdeen stated on April 15 that within 12 months after receiving two doses of the new crown vaccine, people may also need a third dose of vaccine, and it may be every year.

Based on the 1.

It is worth noting that from the perspective of the drug sales revenue rankings of global pharmaceutical companies, as the world's first pharmaceutical company in 2020, Roche's global revenue in 2020 is 49.

More importantly, Pfizer is currently negotiating the supply of new crown vaccine with many governments.

Perhaps, the dark horse at the top of the airborne list is not only BNT162b2.

As a competitor of Pfizer/BioNTech, Moderna’s first-quarter 2021 financial report data shows that the new crown vaccine contributed 90% of its revenue and achieved sales of US$1.

02 It is only a matter of time before K medicine replaces the status of Xiu Mei Le medicine king

If the "spoiler" factor of the new crown vaccine is aside, can Xiumile still sit on the top of the world's best-selling drug list in 2021?

It may be okay in 2021, but it should not be long before.

Judging from the list of the world's best-selling drugs in 2020, there are three super blockbusters with sales exceeding tens of billions of dollars:

Data source: financial reports of pharmaceutical companies

Although Xiumile will still occupy the top position of the world's top 10 best-selling drugs in 2021, it cannot be ignored that the growth rate of Xiumile has slowed down to only 3.

Obviously, it is only a matter of time before Keytruda replaces Xiu Mei Le as the "King of Medicine".

According to Evaluate Pharma’s forecast, Keytruda’s sales in 2021 will reach $16.

Unlike the second-place Keytryda chasing Humira, the third-placed tens of billions of dollars lenalidomide performed relatively stable.
Since BMS acquired Xinji and obtained its heavyweight lenalidomide, the market performance of lenalidomide has been relatively stable.
In 2020, it ranked first in BMS sales, with global sales reaching 12.
18 billion U.
S.
dollars.
With the continuous increase of new indications, the sales of lenalidomide have also increased year by year.
At present, lenalidomide has become the number one blockbuster drug for small-molecule anti-tumor drugs.
As one of the world’s best-selling drugs, according to the first quarter financial report of BMS, lenalidomide’s sales in 2021Q1 were US$2.
944 billion.
It is predicted that the sales of Nalidomide will reach US$12.
7 billion in 2021 and exceed US$13 billion in 2022.

The agency predicts that in 2021, the global sales of 4 drugs will exceed 10 billion U.
S.
dollars at the same time.
In addition to Humira, Keytruda, and Revlimid, which will exceed 10 billion U.
S.
dollars in 2020, Eliquis will also enter this ranking.

Source: EvaluatePharma

According to forecasts, BMS/Pfizer’s anticoagulant Eliquis will return to the $10 billion molecular club in 2021, with an estimated sales of $10.
5 billion.
Eliquis is an oral selective activation factor Xa inhibitor jointly developed by BMS and Pfizer in 2007.
It was first approved in the European Union in 2011 and approved by the FDA in 2012.
Since its listing, Eliquis' sales have increased year by year, setting a sales record of $12.
1 billion in 2019.

In general, judging from the global best-selling drug rankings, tumors and autoimmunity are still the hottest areas.
As Pfizer/BioNtech and Moderna's new crown vaccine may approach or even exceed US$20 billion in sales, it is worth looking forward to whether it will eventually surpass Humira and create a new record.